glp 1 alcohol GLP-1 receptor agonists for the treatment of use disorder GLP-1 Anti-Obesity Rx and Alcohol
Description
Ludvik B, Giorgino F, Jodar E, Frias JP, Fernandez Lando L, Brown K

A recent analysis of pharmacy claims found that 63% of patients starting Wegovy or Zepbound in early 2024 were still taking the drug one year later

10.1016/j.ijcard.2018.12.005 51 SukumaranV.TsuchimochiH.SonobeT.WaddinghamM

Potential side effects to GLP-1 agonists: understanding their safety and tolerability

Advertisement SELECT was designed to determine whether semaglutide can exert protective cardiovascular effects in patients with overweight or obesity in the absence of diabetes

What Happens After 2027